Myasthenia Gravis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Argenx-Halozyme

DelveInsight's "Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Myasthenia Gravis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myasthenia Gravis Market Forecast
https://www.delveinsight.com/sample-request/myasthenia-gravis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Myasthenia Gravis Market Report:
• Among the 7MM countries the Myasthenia Gravis market size was valued ~USD 4,950 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In Aprila 2025, Nipocalimab-aahu is a human IgG1 monoclonal antibody that targets the neonatal Fc receptor (FcRn) with high affinity, leading to decreased levels of circulating IgG. Its approval was based on findings from the Phase 3 Vivacity-MG3 trial (ClinicalTrials.gov ID: NCT04951622), a randomized, double-blind, placebo-controlled study. The trial included adult patients with generalized myasthenia gravis (gMG) classified as class II to IV by the Myasthenia Gravis Foundation of America, who showed an inadequate response to current standard therapies, defined by an MG-ADL score of 6 or higher.
• In April 2025, Impressive findings from the Phase 3 clinical trial (NCT05737160) evaluating the safety and effectiveness of Telitacicept (also known as RC18; brand name: 泰爱®) in individuals with generalized myasthenia gravis (gMG) were presented during the Late-Breaking Science Session at the 2025 American Academy of Neurology (AAN) Annual Meeting.
• In March 2025, Immunovant opted not to seek regulatory approval for its myasthenia gravis (MG) therapy, batoclimab, even though the Phase III trial achieved its primary goal of reducing disease symptoms. Instead, the company plans to use the trial data to support the advancement of its alternative candidate, IMVT-1402. The Phase III randomized study (NCT05403541) evaluated the effects of weekly or bi-weekly batoclimab dosing in acetylcholine receptor antibody-positive (AChR+) patients, measuring improvements through the Myasthenia Gravis Activities of Daily Living (MG-ADL) score over 12 weeks.
• In January 2025, Cartesian Therapeutics, Inc. reported that it has obtained a written agreement from the FDA through the Special Protocol Assessment (SPA) process regarding the design of its upcoming Phase 3 AURORA trial for Descartes-08, the company's lead mRNA cell therapy candidate for treating myasthenia gravis.
• In December 2024, Cartesian Therapeutics shared updated efficacy and safety results from its Phase IIb trial evaluating Descartes-08, an mRNA cell therapy candidate for generalized myasthenia gravis (MG). The findings demonstrated durable responses at 12 months. This open-label, double-blind, placebo-controlled, crossover study (NCT06038474) enrolled 36 symptomatic patients who had previously undergone extensive treatment. Participants were divided evenly, with one group receiving a placebo and the other receiving Descartes-08. Both groups underwent six weekly outpatient infusions, administered without the need for prior chemotherapy-based preconditioning.
• In October 2024, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune disorders, announced plans to present findings from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). The data will be shared at the 2024 Myasthenia Gravis Foundation of America (MGFA) Scientific Session, held during the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting.
• In 2023, the EU4 and the UK generated an estimated USD 893 million in revenue, with projections indicating significant CAGR growth ahead. Among these countries, Germany held the largest market share, followed by the UK, France, and Italy, while Spain contributed the smallest share that year.
• Among the 7MM, the United States led the market in 2023, accounting for the largest portion with approximately 76% share.
• According to DelveInsight's estimates, there were around 287,000 diagnosed prevalent cases of Myasthenia Gravis in the 7MM in 2023, with numbers expected to rise over the forecast period.
• In 2023, approximately 129,000 people in the United States were diagnosed with myasthenia gravis, and this number is anticipated to grow at a projected CAGR over the study period from 2020 to 2034.
• Within the 7MM, the EU4 and the UK together accounted for approximately 125,000 diagnosed prevalent cases of myasthenia gravis, with this number expected to rise throughout the forecast period (2023-2034).
• In 2023, Germany reported the highest number of diagnosed prevalent cases of myasthenia gravis among the EU4 and the UK, with around 39,000 cases, followed by the UK and France. Conversely, Spain recorded the lowest number of diagnosed prevalent cases within this group.
• In 2023, Japan recorded approximately 32,000 diagnosed prevalent cases of myasthenia gravis, and this number is projected to grow at a notable CAGR over time.
• According to the MGFA classification, diagnosed prevalent cases of myasthenia gravis are divided into five categories: Class I (ocular), Class II (mild generalized), Class III (moderate generalized), Class IV (severe generalized), and Class V (intubated). In the US, Class II had the highest estimated number of cases in 2023, totaling around 56,000.
• Key Myasthenia Gravis Companies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others
• Key Myasthenia Gravis Therapies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others
• The Myasthenia Gravis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myasthenia Gravis pipeline products will significantly revolutionize the Myasthenia Gravis market dynamics.

Myasthenia Gravis Overview
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by weakness and fatigue of voluntary muscles. It occurs when the body's immune system mistakenly attacks and damages the communication between nerve cells and muscles, specifically at the neuromuscular junction.

Get a Free sample for the Myasthenia Gravis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/myasthenia-gravis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Myasthenia Gravis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Myasthenia Gravis Epidemiology Segmentation:
The Myasthenia Gravis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Myasthenia Gravis
• Prevalent Cases of Myasthenia Gravis by severity
• Gender-specific Prevalence of Myasthenia Gravis
• Diagnosed Cases of Episodic and Chronic Myasthenia Gravis

Download the report to understand which factors are driving Myasthenia Gravis epidemiology trends @ Myasthenia Gravis Epidemiology Forecast
https://www.delveinsight.com/sample-request/myasthenia-gravis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Myasthenia Gravis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myasthenia Gravis market or expected to get launched during the study period. The analysis covers Myasthenia Gravis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Myasthenia Gravis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Myasthenia Gravis Therapies and Key Companies
• Tolebrutinib: Sanofi
• Descartes-08: Cartesian Therapeutics
• Mezagitamab (TAK-079): Takeda
• DAS-001: DAS Therapeutics, Inc.
• Rozanolixizumab: UCB Biopharma
• Zilucoplan: UCB Biopharma
• Subcutaneous Efgartigimod: Argenx-Halozyme Therapeutics
• Uplizna (Inebilizumab): Horizon Therapeutics
• Enspryng (Satralizumab): Hoffmann-La Roche
• Nipocalimab: Janssen Research & Development, LLC
• Batoclimab: Immunovant Sciences GmbH

Discover more about therapies set to grab major Myasthenia Gravis market share @ Myasthenia Gravis Treatment Landscape
https://www.delveinsight.com/sample-request/myasthenia-gravis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Myasthenia Gravis Market Strengths
• The growing prevalence of myasthenia gravis (MG) and the geriatric population offers a stable market demand for treatments and therapies.
• Myasthenia gravis treatments may qualify for orphan drug status, offering regulatory incentives, such as extended market exclusivity and tax benefits.

Myasthenia Gravis Market Opportunities
• Potential for developing new, more effective therapies, such as gene therapy or targeted biologics, could address unmet medical needs.
• Improved diagnostic techniques using clear biomarkers and an increase in awareness will likely lead to a diagnosis of more patients, expanding the market.

Scope of the Myasthenia Gravis Market Report
• Study Period: 2020-2034
• Coverage: 7MM Countries
• Key Myasthenia Gravis Companies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others
• Key Myasthenia Gravis Therapies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others
• Myasthenia Gravis Therapeutic Assessment: Myasthenia Gravis current marketed and Myasthenia Gravis emerging therapies
• Myasthenia Gravis Market Dynamics: Myasthenia Gravis market drivers and Myasthenia Gravis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Myasthenia Gravis Unmet Needs, KOL's views, Analyst's views, Myasthenia Gravis Market Access and Reimbursement

To know more about Myasthenia Gravis companies working in the treatment market, visit @ Myasthenia Gravis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/myasthenia-gravis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Myasthenia Gravis Market Report Introduction
2. Executive Summary for Myasthenia Gravis
3. SWOT analysis of Myasthenia Gravis
4. Myasthenia Gravis Patient Share (%) Overview at a Glance
5. Myasthenia Gravis Market Overview at a Glance
6. Myasthenia Gravis Disease Background and Overview
7. Myasthenia Gravis Epidemiology and Patient Population
8. Country-Specific Patient Population of Myasthenia Gravis
9. Myasthenia Gravis Current Treatment and Medical Practices
10. Myasthenia Gravis Unmet Needs
11. Myasthenia Gravis Emerging Therapies
12. Myasthenia Gravis Market Outlook
13. Country-Wise Myasthenia Gravis Market Analysis (2020-2034)
14. Myasthenia Gravis Market Access and Reimbursement of Therapies
15. Myasthenia Gravis Market Drivers
16. Myasthenia Gravis Market Barriers
17. Myasthenia Gravis Appendix
18. Myasthenia Gravis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Myasthenia Gravis Pipeline https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Myasthenia Gravis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Myasthenia Gravis market. A detailed picture of the Myasthenia Gravis pipeline landscape is provided, which includes the disease overview and Myasthenia Gravis treatment guidelines.

Myasthenia Gravis Epidemiology https://www.delveinsight.com/report-store/myasthenia-gravis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myasthenia Gravis Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.